Clinical Trial

Positive early trial data for ZP9830 shows promise for a new class of targeted autoimmune therapies, marking a strategic pivot for Zealand Pharma.

A new hair-root innovation from Thai universities uses Riceberry rice to fight hair loss at the cellular level, boosting local farmers and global markets.

Annexon Biosciences spotlights its novel C1q inhibitor, Vonaprument, aiming to be the first therapy to preserve vision in geographic atrophy patients.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

A new study uses PET-CT scans to track CIT-013, a first-in-class antibody targeting the root cause of inflammation in rheumatoid arthritis and HS.

Nawal Ouzren steps down as CEO for personal reasons just after a €60M financing. Chairman Amit Munshi takes over as the biotech faces key milestones.

A genomic test identifies which breast cancer patients truly benefit from extended hormone therapy, a major step toward personalized long-term care.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

With a year of strong growth, key partnerships, and pipeline progress, all eyes are on ALK's upcoming annual results for 2025.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.